Recursion Pharmaceuticals Inc RXRX shares are under pressure Wednesday after new regulatory filings showed that Nvidia Corp NVDA has fully exited its investment in the AI‑focused drug‑discovery ...
Recursion will host a (L)earnings Call on February 25, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The company will broadcast the live stream from Recursion’s X, LinkedIn, and YouTube accounts.
Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is ...
Don't call Recursion Pharmaceuticals (NASDAQ: RXRX) a biotech company. Its management prefers the term "TechBio." While many have been skeptical about TechBio in the past, the reception is changing ...
Zacks Investment Research on MSN
Recursion Pharmaceuticals (RXRX) exceeds market returns: Some facts to consider
Recursion Pharmaceuticals (RXRX) ended the recent trading session at $3.53, demonstrating a +2.02% change from the preceding day's closing price. This move outpaced the S&P 500's daily gain of 0.56%.
If you are trying to figure out whether Recursion Pharmaceuticals is attractively priced or a high risk speculation, a useful ...
Chris Gibson, PhD, Recursion’s co-founder and CEO, discusses exclusively with GEN Edge his company’s ambitious plans to develop 100 pipeline candidates in roughly a decade, the savings in money and ...
Discover the world of Recursive Self-Improvement (RSI) in AI. From I.J. Good's intelligence explosion to modern self-healing code and clinical applications, explore who is developing it, how it works, ...
We believe that Recursion RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is likely to beat expectations when it reports second-quarter 2024 results. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results